Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)

Julie A. Bettinger*, David W. Scheifele, Scott A. Halperin, Wendy Vaudry, Jamie Findlow, Raymond Borrow, Duccio Medini, Raymond Tsang

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)

Abstract

Background: In collaboration with the Canadian Immunization Monitoring Program Active (IMPACT), the National Microbiology Laboratory, the UK Health Protection Agency and Novartis Vaccines, we tested the potential of an investigational 4-component meningococcal B vaccine (4CMenB) to cover Canadian strains circulating from 2006 to 2009. Methods: IMPACT meningococcal surveillance is population based and includes over 50% of Canadian adults and children. All isolates were characterized by Meningococcal Antigen Typing System (MATS) and sequencing for factor H-binding protein (fHbp), Neisseria Heparin Binding Antigen (NHBA) and Neisserial adhesin A (NadA). Results: In total, 157 isolates were tested. Overall, 4CMenB MATS predicted strain coverage was 66% (95% CI: 46-78%), with 26%, 29% and 11% of strains covered by one, two and three vaccine antigens, respectively. The coverage of each antigen was as follows: 13% PorA, 1% NadA, 52% fHbp and 51% NHBA. The majority of strains for clonal complex (cc) 41/44 and cc60 were covered by NHBA; the majority of strains for cc269 and cc32 were covered by fHbp and NHBA.Coverage for two prevalent strains (sequence type (ST)-269 and ST-154) was 95% and 100%, respectively. Conclusions: 4CMenB has the potential to protect against a significant proportion of Canadian invasive MenB strains.

Original languageEnglish
Pages (from-to)124-130
Number of pages7
JournalVaccine
Volume32
Issue number1
DOIs
Publication statusPublished - 17 Dec 2013

Bibliographical note

Funding Information:
Author contributions: J.A. Bettinger is the PI for the study and first author on the manuscript. She is Co-PI for IMPACT's Invasive Meningococcal Surveillance project. She was involved with conception and design of the invasive meningococcal surveillance project and the study reported here as well as data acquisition. She analyzed and interpreted the data and wrote and revised the submitted manuscript. D.W. Scheifele is the IMPACT Data Center Director and Co-PI for IMPACT's Invasive Meningococcal Surveillance project. He was involved with conception and design of the meningococcal surveillance project and the study reported here as well as data acquisition and interpretation of the data. He revised and approved the submitted manuscript. S.A. Halperin is one of two Co-PIs for the IMPACT surveillance network. He was involved with conception and design of the meningococcal surveillance project and the study reported here as well as data acquisition. He revised and approved the submitted manuscript. W. Vaudry is the second of two Co-PIs for the IMPACT surveillance network. She was involved with conception and design of the meningococcal surveillance project, the study reported here and data acquisition. She revised and approved the submitted manuscript. J. Findlow was responsible for characterizing the serogroup B isolates by MATS and sequencing fHbp, NHBA and NadA at the Health Protection Agency. He revised and approved the submitted manuscript. R. Borrow was responsible for characterizing the serogroup B isolates by MATS and sequencing fHbp, NHBA and NadA at the Health Protection Agency and was involved with interpretation of the data. He revised and approved the submitted manuscript. D. Medini provided access to and explanation of the laboratory and statistical methods used in the Plikaytis et al. inter-laboratory study and the Donnelly et al. MATS manuscript. He revised and approved the submitted manuscript. R. Tsang is responsible for the maintenance of the IMPACT N. meningitidis isolate collection at the National Microbiology Laboratory. He was responsible for the serogroup and sequencing typing of the serogroup B isolates and was involved with interpretation of the data. He revised and approved the submitted manuscript. Conflicts of interest: JAB: ad-hoc Advisory Boards (Novartis Vaccines, Canada) and speaker honoraria (Novartis Vaccines, Pfizer Inc., Baxter Inc.). SAH: ad-hoc Advisory Board for Novartis Vaccines, Canada and speaker honoraria in the past year (Novartis Vaccines). DWS: ad hoc Advisory Board for Novartis Vaccines, Canada. WV: Data Safety and Monitoring Board, Novartis Vaccines. RB has performed contract research on behalf of the Health Protection Agency for Baxter Biosciences, GSK, Novartis, Merck, Pfizer and Sanofi Pasteur. JF has performed consultancies for Baxter, GSK, Novartis and Pfizer, received travel support from Baxter Biosciences, GSK, Novartis and Pfizer and performed contract research on behalf of the Health Protection Agency for Baxter Biosciences, GSK, Novartis, Merck, Pfizer and Sanofi Pasteur. DM: employee (Novartis Vaccines). RT: None. Funding statement: The Canadian Immunization Monitoring Program, Active (IMPACT) is a national surveillance initiative managed by the Canadian Paediatric Society and conducted by the IMPACT network of pediatric investigators. From 2002 to 2011, IMPACT meningococcal surveillance was supported by a grant from Sanofi-Pasteur . The additional typing and laboratory testing performed in this study was supported by a grant from Novartis Vaccines & Diagnostics . JAB is supported by a Career Investigator Award from the Michael Smith Foundation for Health Research .

Keywords

  • 4CMenB coverage
  • Invasive meningococcal disease
  • Meningitis
  • Meningococcal Antigen Typing System
  • Serogroup B vaccines

Fingerprint

Dive into the research topics of 'Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)'. Together they form a unique fingerprint.

Cite this